InMed Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IMLFF InMed Pharmaceuticals Inc
PNW Pinnacle West Capital Corp
AAPL Apple Inc
NAII Natural Alternatives International Inc
SJMiv.P Invesco BulletShares 2022 Hi Yld Corp Bd ETF
INTC Intel Corp
VAL Valaris PLC
GE General Electric Co
XOM Exxon Mobil Corp
MSFT Microsoft Corp

Health Care : Biotechnology | Small Cap Growth
Based in CanadaCompany profile

InMed Pharmaceuticals Inc. is a pre-clinical-stage biopharmaceutical company. The Company specializes in the research and development of cannabinoid-based therapies combined with drug delivery systems. The Company operates through the segment of research and development of pharmaceutical cannabis based-therapies. The Company is working on two products, which include INM-750, for the treatment of Epidermolysis Bullosa (EB), and INM-085, for the treatment of Glaucoma. The INM-750 is a therapy developed for EB designed specifically to modulate disease activity and to alleviate symptoms. The INM-085 is designed as a dual-action cannabinoid ocular therapy. INM-085 is designed as a topical formulation to be administered directly to the eye. It is working on the development of several cannabinoid-based treatments for multiple diseases, including ocular, dermatology, cancer, inflammation, pain and arthritis disease areas. Its subsidiary is Biogen Sciences Inc. (BSI).

Closing Price
Day's Change
0.0234 (12.58%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

UPDATE: Weekend roundup: Skip the new iPhones | Tech gems | Flipping planes

7:11 am ET September 21, 2019 (MarketWatch)

By Philip van Doorn, MarketWatch

Also: What not to do in the wake of the Federal Reserve's latest interest-rate cut

This week, MarketWatch readers worried about the implications of the Federal Reserve's rate cut -- and whether they should upgrade to the new iPhone.

The decision on Apple's latest offering might be the easiest, although certainly as divisive. Columnist Jurica Dujmovic dismisses the iPhone 11 as overpriced and behind the times. He stacks it up against offerings from Samsung and others. Read about his findings here ( Readers, of course, had their own ideas, so join the conversation.

Here are more articles you shouldn't miss.

What to do about the Fed

Fed officials are divided ( about the economic outlook, so what does that mean for your finances?

Rethink that. Jacob Passy offers up suggestions of what not to do ( in the wake of the Federal Reserve's interest-rate cut this week.

Meanwhile, Fed watchers are no less divided than the policy makers. Peter Morici takes the Fed and European Central Bank to task ( for not learning from their mistakes, and Barry Bannister, chief equity strategist at Stifel, says the Fed remains too tightfisted (

Hidden tech gems

Michael Brush shares five out-of-the-way technology companies, including one that may benefit greatly as China invests ( in specialized microchip technology that it has traditionally relied on the U.S. to provide.

Don't forget the midcaps

Financial media coverage of stocks, funds and ETFs nearly always focuses on either the largest companies or the smallest. Amy Zhang of Alger and Crit Thomas of Touchstone Investments make the case for midcap stocks as the best performers ( over the long term.

Also: An analyst calls for a 50% drop ( in Roku.(ROKU)

The big down payment

I remember thinking during my college years that I might never be able to buy a home because it would be so difficult to scrape together money for the down payment while also paying rent. If anything, the situation has become much more difficult. Here's how millennials are getting it done ( and what the consequences might be.

Dealing with the gold-digging sister-in-law

MarketWatch's Moneyist ( weighs in on this latest episode of relatives behaving badly ( So do MarketWatch readers:

'Retirement' doesn't mean quitting

Mitch Tuchman points out how dangerous the first year of retirement can be to one's health, argues that target ages for ending a career are outdated and describes a more balanced approach ( to financial independence.

Maria Bartiromo weighs in on her own retirement plans ( in an interview with Allesandra Malito.

Retiring abroad ... in Costa Rica

Martin Farber was living in a Chicago suburb and never expected to retire in Costa Rica ( First impressions, however, turned out to be misleading.

The risk of living together in your golden years

Many more people over the age of 50 choose to live together rather than get married. But the laws favored married couples. Brad Wiewel, an estate planning lawyer, explains what to do so that it's much easier for partners to help each other (

Terry Bradshaw's $900,000 real estate loss

"I lost a lot, but it could have been a lot worse," the former Steelers quarterback tells Weston Blasi.

So now he flips ( $5 million airplanes.

Want more from MarketWatch? Check out our Personal Finance Daily ( or other newsletters (, and get the latest news, personal finance and investing advice.

-Philip van Doorn; 415-439-6400;

(END) Dow Jones Newswires

September 21, 2019 07:11 ET (11:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.